Medtronic Announces Appeal Decision in Patent Litigation with DePuy Spine

MINNEAPOLIS--(Business Wire)--
Medtronic, Inc. (NYSE:MDT), today announced results from a Federal Circuit Court
review of a December 2007 patent infringement verdict regarding the Vertex line
of multiaxial screws, which are no longer on the market. The Appeals Court
upheld the verdict of patent infringement, but reversed a substantial portion of
the damages award to DePuy Spine. The Appeals Court also reversed a sanctions
determination against Medtronic, finding that it was legally incorrect and could
not be sustained. The Appeals Court affirmed an award of $149.1 million in lost
profits, but eliminated another $77.2 million in damages to DePuy Spine, along
with another approximate $10.5 million in sanctions and attorneys` fees.

"We are pleased that the judgment will be reduced by a very substantial amount
as a result of this appeal, and that the right to a vigorous trial defense was
upheld," said Steve La Neve, president of the Spinal and Biologics business and
senior vice president at Medtronic. "It is important to note that this case has
no bearing on our current Vertex Select and OC Systems."

The case will now be remanded to the trial court for calculation of the reduced
judgment, which will include amounts both for post-judgment and prejudgment
interest on the damages.

About Medtronic

Medtronic, Inc. (www.medtronic.com), headquartered in Minneapolis, is the
world`s leading medical technology company, alleviating pain, restoring health,
and extending life for people with chronic disease.

Any forward-looking statements are subject to risks and uncertainties such as
those described in Medtronic`s Annual Report on Form 10-K for the year ended
April 25, 2008.Actual results may differ materially from anticipated results.

Medtronic, Inc.
Marybeth Thorsgaard, 763-505-2644
Public Relations
Jeff Warren, 763-505-2696
Investor Relations

Copyright Business Wire 2009